Merck Gains as Investors Cheer New Phase 3 Oncology Data

Merck & Co. (MRK) is up 3.5% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver is fresh enthusiasm around Merck’s oncology pipeline after the company highlighted multiple late-stage cancer readouts for ESMO 2026, including pivotal Phase 3 data tied to Keytruda and other assets. The move also appears consistent with continued bullish positioning ahead of Merck’s Oct. 26 oncology investor event and its Oct. 29 third-quarter earnings call.

Details:

Merck said it will present first-time pivotal Phase 3 results for intismeran autogene plus Keytruda in resected stage IIB-IV melanoma, with improvements in recurrence-free survival and distant metastasis-free survival versus Keytruda alone.

The company also flagged Phase 3 data for sacituzumab tirumotecan in advanced or recurrent endometrial cancer, describing it as the first and only Phase 3 trial of a TROP2-directed antibody-drug conjugate to improve both overall survival and progression-free survival in that setting.

Merck scheduled an oncology investor event for Oct. 26 in Madrid to discuss strategy and programs, giving investors a near-term catalyst to focus on after the new ESMO disclosures.

Recent analyst-tracked updates show higher price targets and expectations for strong oncology data, which may have reinforced momentum around the stock.

Sources:

Merck, TipRanks, Merck Investor Relations

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$MRK Insider Trading Activity

$MRK insiders have traded $MRK stock on the open market 17 times in the past 6 months. Of those trades, 0 have been purchases and 17 have been sales.

Here’s a breakdown of recent trading of $MRK stock by insiders over the last 6 months:

JENNIFER ZACHARY (EVP, General Counsel) sold 80,315 shares for an estimated $10,718,494
DAVID MICHAEL WILLIAMS (EVP,Chief Info&Digital Officer) has made 0 purchases and 3 sales selling 52,847 shares for an estimated $6,805,145.
RICHARD R. DELUCA (EVP&Pres, Merck Animal Heallth) has made 0 purchases and 8 sales selling 51,370 shares for an estimated $6,731,142.
CHIRFI GUINDO (EVP, Access, Policy & Comms) has made 0 purchases and 2 sales selling 25,000 shares for an estimated $3,315,000.
DAVID R. MARALDO (EVP & Pres. MMD) has made 0 purchases and 3 sales selling 18,706 shares for an estimated $2,407,797.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$MRK Hedge Fund Activity

We have seen 1,766 institutional investors add shares of $MRK stock to their portfolio, and 1,620 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 54,365,289 shares (+inf%) to their portfolio in Q2 2026, for an estimated $6,985,939,636
JPMORGAN CHASE & CO added 43,886,420 shares (+inf%) to their portfolio in Q2 2026, for an estimated $5,639,404,970
CAPITAL INTERNATIONAL INVESTORS added 14,516,428 shares (+1668.1%) to their portfolio in Q2 2026, for an estimated $1,865,360,998
FISHER ASSET MANAGEMENT, LLC added 12,079,979 shares (+45.7%) to their portfolio in Q2 2026, for an estimated $1,552,277,301
NORDEA INVESTMENT MANAGEMENT AB removed 5,024,243 shares (-58.9%) from their portfolio in Q2 2026, for an estimated $645,615,225
CHARLES SCHWAB INVESTMENT MANAGEMENT INC added 4,600,064 shares (+9.2%) to their portfolio in Q2 2026, for an estimated $591,108,224
PRICE T ROWE ASSOCIATES INC /MD/ removed 4,524,046 shares (-19.6%) from their portfolio in Q2 2026, for an estimated $581,339,911

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$MRK Government Contracts

We have seen $3,643,517 of award payments to $MRK over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

ERVEBO PROCUREMENT: $190,468

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.

$MRK Congressional Stock Trading

Members of Congress have traded $MRK stock 3 times in the past 6 months. Of those trades, 2 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $MRK stock by members of Congress over the last 6 months:

REPRESENTATIVE MARIA ELVIRA SALAZAR has traded it 3 times. They made 2 purchases worth up to $100,000 on 08/19 and 1 sale worth up to $15,000 on 09/24.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$MRK Price Targets

Multiple analysts have issued price targets for $MRK recently. We have seen 8 analysts offer price targets for $MRK in the last 6 months, with a median target of $139.5.

Here are some recent targets:

Terence Flynn from Morgan Stanley set a target price of $113.0 on 07/09/2026
Mohit Bansal from Wells Fargo set a target price of $150.0 on 07/08/2026
Trung Huynh from RBC Capital set a target price of $142.0 on 07/08/2026
Carter Gould from Cantor Fitzgerald set a target price of $120.0 on 07/06/2026
Louise Chen from Scotiabank set a target price of $155.0 on 06/30/2026
Tim Anderson from B of A Securities set a target price of $141.0 on 06/30/2026
An analyst from CICC set a target price of $138.0 on 06/24/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.